We are live on ! Find out more
IMMU

Immunomedics Inc
IMMU

Delisted

IMMU was delisted on the 22nd of October, 2020.

Back to rankings

150 hedge funds and large institutions have $1.62B invested in Immunomedics Inc in 2017 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 55 increasing their positions, 43 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

169% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 13

112% more capital invested

Capital invested by funds: $766M → $1.62B (+$856M)

88% more call options, than puts

Call options by funds: $86.7M | Put options by funds: $46M

43% more funds holding in top 10

Funds holding in top 10: 7 → 10 (+3)

28% more repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 43

15% more funds holding

Funds holding: 130 → 150 (+20)

Holders
150
Holders Change
+20
Holders Change %
+15.38%
% of All Funds
3.74%
Holding in Top 10
10
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+42.86%
% of All Funds
0.25%
New
35
Increased
55
Reduced
43
Closed
13
Calls
$86.7M
Puts
$46M
Net Calls
+$40.6M
Net Calls Change
+$25.6M

Top Buyers

Rank Fund Capital Flow
1
ACP
Acuta Capital Partners
California
+$51.2M
2
O
OrbiMed
New York
+$50.5M
3
ACA
Avoro Capital Advisors
New York
+$42.4M
4
EC
EcoR1 Capital
California
+$28.5M
5
NMC
NEA Management Company
Maryland
+$27.6M

Top Sellers

Rank Fund Capital Flow
1
FCM
Farallon Capital Management
California
-$37.3M
2
Millennium Management
Millennium Management
New York
-$13.1M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$9.27M
4
FLAM
First Light Asset Management
Minnesota
-$7.35M
5
AC
Ascend Capital
California
-$5.12M
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
26
Goldman Sachs
New York
$12.9M +$134K +13,398 +1%
Geode Capital Management
27
Geode Capital Management
Massachusetts
$12.7M +$448K +44,913 +5%
OM
28
Opaleye Management
Massachusetts
$12.6M -$12K -1,200 -0.1%
NC
29
Nexthera Capital
New York
$11.1M +$7.89M +792,106 New
DCM
30
Driehaus Capital Management
Illinois
$11M +$724K +72,649 +10%
HCM
31
Highbridge Capital Management
New York
$10.3M +$7.37M +739,371 New
Bank of New York Mellon
32
Bank of New York Mellon
New York
$9.53M +$531K +53,284 +8%
Two Sigma Investments
33
Two Sigma Investments
New York
$9.26M +$1.72M +172,127 +35%
PAM
34
Panagora Asset Management
Massachusetts
$9.08M +$59.4K +5,964 +0.9%
Invesco
35
Invesco
Georgia
$8.74M +$2.63M +263,795 +73%
Ameriprise
36
Ameriprise
Minnesota
$8.17M -$2.26M -226,429 -28%
DM
37
Deerfield Management
New York
$8.14M +$5.8M +582,000 New
RPAM
38
Rhenman & Partners Asset Management
Sweden
$6.99M -$295K -29,610 -6%
IHM
39
Iguana Healthcare Management
New York
$6.99M +$1.74M +175,000 +54%
CS
40
Candriam SCA
Luxembourg
$6.91M -$553K -55,500 -10%
Charles Schwab
41
Charles Schwab
California
$6.55M +$2.8M +281,032 +150%
DCM
42
DAFNA Capital Management
California
$6.44M -$1.77M -177,249 -28%
SFM
43
Sphera Funds Management
Israel
$6.29M -$997K -100,000 -18%
Morgan Stanley
44
Morgan Stanley
New York
$6.14M +$2.43M +244,029 +125%
WAM
45
Wolverine Asset Management
Illinois
$5.74M +$4.09M +410,446 New
EI
46
EAM Investors
California
$5.42M -$1.19M -119,498 -24%
GAM
47
Gotham Asset Management
New York
$5.16M +$985K +98,799 +37%
Two Sigma Advisers
48
Two Sigma Advisers
New York
$4.69M +$2.04M +204,895 +157%
NIP
49
Nicholas Investment Partners
California
$4.67M +$3.33M +334,279 New
CEP
50
Chicago Equity Partners
Illinois
$4.52M +$808K +81,060 +33%
1
2
3 4 5

IMMU Hedge Fund Activity: Q3 2017 in Review

150 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Immunomedics Inc (IMMU) for Q3 2017, worth a combined $1.62B — up 112% from $766M a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new IMMU positions and 13 closed out — a net gain of 22 holders — while 55 added to existing stakes and 43 trimmed.

The largest buyer was Acuta Capital Partners, adding an estimated $51.2M. The largest seller was Farallon Capital Management, exiting entirely with an estimated $37.3M sold.

  • 150 institutional investors held Immunomedics Inc (IMMU) as of Q3 2017, up from 130 in Q2 2017.
  • Funds reported $1.62B of Immunomedics Inc stock for Q3 2017, up 112% quarter-over-quarter.
  • 35 funds opened new Immunomedics Inc positions in Q3 2017 and 13 closed out, a net change of +22 holders.
  • The largest Immunomedics Inc buyer in Q3 2017 was Acuta Capital Partners, an estimated $51.2M added.
  • The largest Immunomedics Inc seller in Q3 2017 was Farallon Capital Management, an estimated $37.3M sold.

Based on aggregated 13F filings for Q3 2017.